HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50

Benzinga · 2d ago
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $50.